These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1001871)

  • 1. Cell population size dependency of therapeutic effect of divided dosage of 1-beta-D-arabinofuranosylcytosine.
    Abe I; Sato S
    Gan; 1976 Jun; 67(3):461-4. PubMed ID: 1001871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schedule optimization of hydroxyurea and 1-beta-D-arabinofuranosylcytosine in sarcoma 180 in vitro.
    Shackney SE; Ford SS; Occhipinti SJ; Ritch PS; Riccardi R; Erickson BW
    Cancer Res; 1982 Nov; 42(11):4339-47. PubMed ID: 7127279
    [No Abstract]   [Full Text] [Related]  

  • 4. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
    Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin and vincristine with methionine depletion contributed to survival in the Yoshida sarcoma bearing rats.
    Nagahama T; Goseki N; Endo M
    Anticancer Res; 1998; 18(1A):25-31. PubMed ID: 9568051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the effect of cyclophosphamide on Yoshida sarcoma ascites cells implanted into the colon wall of rats.
    Bhide S; Habs M; Reinhold H; Schmähl D
    Arzneimittelforschung; 1979; 29(3):477-9. PubMed ID: 582732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in whole body, muscle, liver, and tumor tissue protein synthesis and degradation in Novikoff hepatoma and Yoshida sarcoma tumor growth studied in vivo.
    Tayek JA; Blackburn GL; Bistrian BR
    Cancer Res; 1988 Mar; 48(6):1554-8. PubMed ID: 3345528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro-in vivo studies on the susceptibility of the solid Yoshida sarcoma to drugs and hyperthermia (42 degrees).
    Dickson JA; Suzangar M
    Cancer Res; 1974 Jun; 34(6):1263-74. PubMed ID: 4363651
    [No Abstract]   [Full Text] [Related]  

  • 9. Schedule dependency of anticancer effect of 1-beta-D-arabinofuranosylcytosine on rat ascites hepatomas.
    Abe I; Sato S; Watanabe M; Sato H
    Sci Rep Res Inst Tohoku Univ Med; 1978 Sep; 25(1-2):20-3. PubMed ID: 741221
    [No Abstract]   [Full Text] [Related]  

  • 10. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
    [No Abstract]   [Full Text] [Related]  

  • 11. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
    Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA; Morgenstern B; Capizzi RL
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.
    Cadman E; Eiferman F
    J Clin Invest; 1979 Sep; 64(3):788-97. PubMed ID: 288743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles.
    Mayhew E; Papahadjopoulos D; Rustum YM; Dave C
    Cancer Res; 1976 Dec; 36(12):4406-11. PubMed ID: 187321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An experimental postoperative metastasis system using Yoshida sarcoma inoculated subcutaneously into footpad.
    Imai R; Ashizawa T; Nakamura N
    Gan; 1975 Feb; 66(1):69-73. PubMed ID: 1158072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of drug cytotoxicity by recruitment of leukemic myeloblasts with humoral stimulation.
    Karp JE; Burke PJ
    Cancer Res; 1976 Oct; 36(10):3600-3. PubMed ID: 1066183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
    Colly LP; Peters WG; Willemze R
    Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
    Caron N; Lee SH; Kimball AP
    Cancer Res; 1977 Sep; 37(9):3274-9. PubMed ID: 884674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
    Vaughan WP; Burke PJ
    Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.